research on retatrutide Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

The limitations include the relatively small sample size of the MASLD substudy, the geographic and racial homogeneity of the sample (United States only and majority white), the exclusion of patients with T2D, the absence of liver histology, the lack of enrichment for MASH or significant fibrosis, the lack of multiplicity control given the large number of statistical assessments and the absence of 48-week MRI data for 56.1% of participants, which limits interpretation of the dose-response relationship for liver fat reduction at 48 weeks

Clinical access is equally strong, since unlimited provider visits are included in every plan

You have tried first-line treatments such as metformin or other antidiabetic medications

Treating reproductive-aged women with glucagon-like peptide-1 receptor agonists: what are the clinical considerations